The expansion is fueled by rising demand for advanced therapeutics in oncology, precision neurology, and cardiovascular care. As therapies involving antisense oligonucleotides and mRNA-based vaccines scale to commercial production, synthesis providers are forced to abandon legacy laboratory-scale processes in favor of high-throughput, continuous-flow platforms. This transition is supported by regulatory bodies like the FDA and EMA, which have introduced new frameworks for the safety assessment and manufacturing of synthetic oligonucleotides.

North America currently leads the global market, anchored by robust supply chains and favorable regulatory environments that encourage rapid commercialization. Antisense oligonucleotide drugs remain the dominant segment, driven by the clinical success of treatments for rare conditions such as spinal muscular atrophy. Major industry participants, including Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies, are aggressively expanding their manufacturing capabilities to keep pace with the evolving requirements of gene-based medicine and personalized treatment protocols.